For years, the question was often whether people with T1D should be using these medications at all
It is important to note that no randomized trial has included a head-to-toe comparison between these two drugs, to evaluate their relative roles in preventing kidney failure and death among patients with diabetes and CKD, especially in patients with varying baseline kidney function, albuminuria severity, and comorbidities such as cardiovascular disease or obesity. Read More About Kidney Disease Lisa Foster Lisa Foster is a mom of 3 daughters and 1 perfect grandchild, a puzzle lover, writer and HealthTree advocate
What happens to my payment if I am determined medically ineligible after submitting intake
With a background that includes significant work at a pharmaceutical company developing obesity drugs, the trajectory of Dr
How to Talk to Your Provider About GLP-1 Microdosing If youre considering GLP-1 microdosing, come to your appointment prepared
The FDA approved semaglutide (Wegovy) for chronic weight management in 2021, marking a significant expansion of GLP-1 RA use beyond glucose control
